Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a regulator of low-density lipoprotein cholesterol (LDL-C) receptor (LDL-R) recycling and, thus, is a determinant of plasma LDL-C concentration. We sought to determine the relation between serum concentrations of PCSK9 and LDL-C while considering a variety of influential variables, including treatment for dyslipidemia. Using a prospective lipid clinic registry, we evaluated clinical variables, the results of advanced lipid testing, and PCSK9 concentrations determined by immunoassay. We evaluated the relationship between directly measured LDL-C and PCSK9 in serum by performing a simple linear regression. Correlation analyses were performed to examine the relationships of PCSK9 to other clinical and laboratory values and to test for differences in median PCSK9 across patient groups. Factors identified as potential predictors were considered jointly in a multivariate model. For the 26 patients in the analyses, a relationship was not detected between LDL-C and PCSK9 ( r = 0.009, P = 0.97); however, PCSK9 was correlated with C-peptide ( r = 0.48; P = 0.01) and heart rate ( r = 0.52; P = 0.006). Median PCSK9 values differed between statin users (284.0 ng/mL [quartile 1 = 241.0, quartile 3 = 468.0]) and nonusers (219.0 ng/mL [quartile 1 = 151.0, quartile 3 = 228.0]; P = 0.02). More investigation is needed to evaluate the relationship between LDL and PCSK9, as well as the determinants of PCSK9, a major factor regulating cholesterol concentrations. A bout 73.5 million (31.7%) adults in America have high levels (≥130 mg/dL) of low-density lipoprotein cholesterol (LDL-C), which is a causative factor for myocardial infarction, ischemic stroke, and cardiovascular death ( 1 ). LDL-C receptors (LDL-R) are found in high density on the surface of hepatocytes and work to remove cholesterol from the blood; however, the proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme binds to LDL-R, targets the LDL-R complex for lysosomal destruction, and prevents recycling of the LDL-R to the surface ( Figure 1 ). When PCSK9 is removed, it cannot bind with LDL-R, which in turn allows the LDL-R to remove larger quantities of cholesterol from the blood than would otherwise be possible. Inhibiting the PCSK9 enzyme has been shown to lower cholesterol an average of 45% to 60% from baseline, irrespective of starting LDL-C and background treatment. Th e US Food and Drug Administration approved the fi rst two PCSK9 inhibitors, alirocumab and evolocumab, Relation between proprotein convertase subtilisin/kexin type 9 and directly measured low-density lipoprotein cholesterol 
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Th e Baylor Preventive Cardiology and Advanced Lipidology Program was conceived to evaluate and manage patients with family histories of premature cardiovascular death, healed myocardial infarction, and acute coronary syndrome events despite optimal medical therapy. A registry was created using patients referred to the program at the Baylor Heart and Vascular Hospital, Dallas, Texas, and the Baylor Heart Hospital, Plano, Texas. Th is paper describes these patients with respect to serum PCSK9 concentrations, catabolic determinants including apolipoprotein and lipid fractions, resultant LDL-C, other atherogenic lipid particles, the eff ect of PCSK9 on LDL, and factors contributing to PCSK9.
METHODS
Patients who were referred to the Baylor Preventive Cardiology and Advanced Lipidology Program were added to the preventive cardiology registry beginning in 2015 after informed consent was obtained. Th is study was approved by Baylor's institutional review board. Laboratory values were provided via Atherotech, Inc. (Birmingham, AL). PCSK9 concentrations were measured in serum via a commercial quantitative sandwich enzyme immunoassay that utilized an anti-PCSK9 polyclonal antibody as the capture antibody.
We examined patients in this registry with available laboratory results as of April 7, 2016 . We imputed values for LDL particle concentration, heart rate (HR), systolic blood pressure, and diastolic blood pressure, which were missing at <8%. We fi rst studied the distributions of directly measured LDL-C and total secreted PCSK9 and then analyzed the strength of their linear relationship by performing a simple linear regression. We performed correlation ( r ) analyses using Pearson's correlation and Spearman's rank correlation, as appropriate, to examine the relationship of PCSK9 and other clinical and laboratory values. We tested for diff erences in median PCSK9 across patient characteristic groups using the Wilcoxon rank sum test (for groups with >5 patients). Th ose identifi ed as potential predictors were considered jointly in a multivariate model using a stepwise selection method. Categorical variables are reported as frequencies and percents. Continuous variables are reported as means ± standard deviations or medians [25%, 75%], if skewed.
RESULTS
Th ere were 26 patients in the preventive cardiology registry with available laboratory results as of April 7, 2016 . Th e characteristics of these patients are presented in Table 1 . Patients were primarily Caucasian (24; 92.3%) males (15; 57.7%), with an average age (± standard deviation) of 50.1 ± 13.7 years. Half ( 13 ) of the patients had hypertension, and over one-third (9; 34.6%) had a recent percutaneous coronary intervention. Although there were 2 (7.7%) subjects with diabetes, 3 subjects were taking diabetes medication (the subject without diabetes was taking metformin). Th e average patient was overweight, with a body mass index of 28.4 ± 6.4 kg/m 2 .
Th e smoothed kernel densities of total secreted PCSK9 and LDL-C are shown in Figure 2 . PCSK9 was heavily skewed to the right, with a median of 253 [219, 336] ng/mL. LDL-C was mostly symmetrical with a mean of 107.7 ± 43.1 mg/dL. Only 0.01% of the variability in LDL-C was explained by the linear regression of PCSK9 on LDL-C; a statistically signifi cant linear relationship was not detected ( r = 0.009, P = 0.97). Th e regression of PCSK9 on LDL-C along with the 95% confi dence interval for mean predicted values is presented in Figure 3 .
A moderate positive linear correlation was detected between PCSK9 and C-peptide ( r = 0.48; P = 0.01). A similar moderate positive linear relationship was detected between PCSK9 and HR ( r = 0.52; P = 0.006). Th e following variables did not have a signifi cant correlation with PCSK9: total cholesterol, LDL Table 2 .
Patients taking statins had a median PCSK9 value of 284.0 ng/mL [241.0, 468.0], while patients not taking a statin had a median PCSK9 of 219.0 ng/mL [151.0, 228.0]; a signifi cant diff erence in median PCSK9 was detected between these two groups ( P = 0.02). In contrast, median PCSK9 did not diff er signifi cantly by gender ( P = 0.83), presence of hypertension ( P = 0.66), or use of anticoagulation medication ( P = 0.63). Th e mean PCSK9 did not diff er for those who had a recent percutaneous intervention ( P = 0.07) or for those taking a beta-blocker ( P = 0.19).
Based on the correlation analyses and hypothesis tests, C-peptide, HR, and statin use were identifi ed as variables to be considered for a multivariate model of PCSK9. A stepwise selection method identifi ed the optimal model of PCSK9 to have only one predictor, C-peptide (overall P = 0.01), which had a moderate positive correlation of r = 0.48. We confi rmed this result by building a multivariate model utilizing all three predictors, which resulted in an overall P value of 0.08.
DISCUSSION
We found that in a small sample with detailed clinical and laboratory measures, there was no signifi cant linear relation between directly measured LDL-C and PCSK9. In contrast, factors such as C-peptide and HR, which may refl ect neurohormonal activation, appeared to have relationships to PCSK9 concentration ( 4 ) . A relationship was also detected between statin use and PCSK9 concentration.
A larger study (n = 3138) conducted in Dallas in the early 2000s created a sample representative of the population characteristics from that geographical area. For subjects not on statins, the study reported a median PCSK9 serum level of 487 (range 22-2988 ng/mL) and observed signifi cantly higher levels for women than men. Th ere was also a weak correlation between PCSK9 and LDL-C ( r = 0.24), as well as with triglycerides, insulin, and glucose ( 5 ) . Similarly, a literature review by Lambert et al stated that studies consistently report positive correlations ( r = 0.15-0.58) between circulating PCSK9 and LDL-C despite the fact that PCSK9 concentrations are not ideal surrogates for PCSK9 function ( 6 -9 ) . For these reasons, we anticipated fi nding a relationship between LDL-C and PCSK9 in our sample. Interestingly, 65.4% of the patients in our study were taking a statin, a higher proportion than typically observed in populationbased studies ( 10 ) . We observed a 30% higher concentration of PCSK9 in statin users, which may account for the reduced observed association between LDL-C and PCSK9, as statin use has been shown to increase the variability in this relationship ( 11 ) . Th e observed treatment eff ect of statins on PCSK9 was in line with previous estimates of 14% to 47% ( 9 ) . Our study adds to previous reports from larger populations in that we used directly measured LDL-C instead of a calculated value, thus enhancing precision of this measure and reducing the infl uence of triglycerides on the computation of LDL-C ( 12, 13 ).
We found a moderate correlation ( r = 0.48) between PCSK9 and C-peptide. Th is may support previous reports of PCSK9's relationships with insulin and glucose, as C-peptide is the stable insulin fragment and is a correlate of both plasma glucose and insulin resistance ( 9 ) . Higher PCSK9 concentrations in those with hyperinsulinemia or insulin resistance may explain the modestly higher LDL-C values described in this population. Consistent with these observations, insulin resistance and the metabolic syndrome are associated with activation of the sympathetic nervous system, and this may have been refl ected in the increased HR values we observed. We also detected a moderate correlation ( r = 0.58; P = 0.002) between C-peptide and age, which was consistent with previous reports Figure 2 . Smoothed kernel density plots of proprotein convertase subtilisin/kexin type 9 (PCSK9) (ng/mL) and low-density lipoprotein cholesterol (LDL-C) (mg/dL). Figure 3 . Linear regression of proprotein convertase subtilisin/kexin type 9 (ng/mL) on low-density lipoprotein (mg/dL).
for older patients, but did not detect a relationship between PCSK9 and age. Th e patient with the highest value of PCSK9 (>1000 ng/mL) was the oldest patient in the sample (78.6 years) and had a phenotype of heterozygous familial hypercholesterolemia with a treated LDL-C of 79 mg/dL; he was overweight (body mass index = 28.2 kg/m 2 ), hypertensive, had extensive coronary artery disease with a prior bypass surgery, and was taking a statin. Th e patient had been taking alirocumab biweekly since October 2015. His lab draw included in this analysis occurred 10 days after the second administration of the drug. He was suspected of having a gain-of-function mutation of PCSK9 , which results in high levels of LDL-C ( 14 ) .
Th is study had all of the limitations of a small, cross-sectional pilot. Th e generalizability of these results is limited due to the small sample size and lack of racial diversity (>90% Caucasian). Diff erences in fasting times and other clinical factors could have played a role in preanalytic variability of PCSK9 concentrations. It is possible that the use of a polyclonal antibody as the capture antibody to measure PCSK9 in the assay created another level of analytic variability. Th e assay used to yield PCSK9 results had an upper limit of detection of 1000 ng/mL; however, only one patient had a value exceeding the upper limit, so it is unlikely that the quality of the analyses suff ered due to the upper detection limit. Because proinsulin was not measured, we were unable to assess its relationship with PCSK9 or C-peptide. Laboratory values were drawn only one time per patient; hence the data presented in this manuscript were not robust to fl uctuations, and we cannot make inferences on serial changes over time.
In conclusion, when using directly measured LDL-C in a mixed population of statin-treated and nontreated patients, we did not fi nd an association between PCSK9 and LDL-C. PCSK9 had a signifi cant linear relation with C-peptide and HR individually; however, the variables were only moderately associated, with correlations of approximately 0.5. Th is work also confi rmed the infl uence of statins, which were associated with a 30% increase in PCSK9 levels. More work is needed to evaluate the relationship between LDL and PCSK9, as well as the determinants of PCSK9, a major factor regulating cholesterol concentrations. 
